Pembrolizumab vs Sitagliptin
Pembrolizumab vs Sitagliptin: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Sitagliptin.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Sitagliptin: DPP-4 inhibitor increasing incretin levels.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days; Sitagliptin — 12.4 hours.
Chemical Properties
Molecular Formula: Sitagliptin — C16H15F6N5O.
Molecular Weight: Sitagliptin — 407.3140 g/mol.
Type: Pembrolizumab — Antibody; Sitagliptin — Small molecule.